Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population. This is an ASCO Meeting ...

A new familial lung cancer caused by an inherited mutation in EGFR has been described in a study published online Oct. 23 in the Journal of Clinical Oncology. Geoffrey R. Oxnard, M.D., from the ...

Clinical implications of the T790M mutation in disease characteristics and treatment response in patients with EGFR-mutated NSCLC. T790M+ on osimertinib 1/8 (12.5%) 1/7 (14%) 1.0 mEGFR (non-T790M) ...

CO-1686 was assigned breakthrough designation by the FDA as monotherapy for the treatment of EGFR-mutant NSCLC patients. Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and ...

VIENNA — For patients with non-small cell lung cancer (NSCLC) carrying the specific T790M mutation in the epidermal growth factor receptor (EGFR) gene, there is now a new standard of care, say experts ...

This novel next-generation EGFR inhibitor targets mutated EGFR signals in NSCLC, including two common mutations called C797S and T790M. These mutations are a major cause of treatment resistance after ...

AstraZeneca today announced that the European Commission (EC) has granted conditional marketing authorisation for TAGRISSO™ (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult ...

Dr. Priya Hays discusses the mechanisms of treatment resistance in cancer, highlighting their significance for developing ...

The epidermal growth factor receptor (EGFR) is highly expressed or mutated in cancers such as non-small cell lung cancer and plays a critical role in the development of cancer, causing increased ...

At its December meeting, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion for Aumseqa (aumolertinib mesylate, SFL Pharmaceuticals ...